Comparative Pharmacology
Head-to-head clinical analysis: CEFMAX versus KEFUROX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFMAX versus KEFUROX IN PLASTIC CONTAINER.
CEFMAX vs KEFUROX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic